Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 16.

Cornec-Le Gall, Emilie; Blais, Jaime D; Irazabal, Maria V; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ron D; Chapman, Arlene B; Czerwiec, Frank S; Ouyang, John; Heyer, Christina M; Senum, Sarah R; Le Meur, Yannick; Torres, Vicente E; Harris, Peter C (2018). Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology, Dialysis, Transplantation, 33(4):645-652.

Harris, Tess; Sandford, Richard; de Coninck, Brenda; Devuyst, Olivier; Drenth, Joost P H; Ecder, Tevfik; Kent, Alastair; Gansevoort, Ron T; Górriz, José Luis; Ong, Albert C M; Pirson, Yves; Torres, Vicente E; Budde, Klemens; Clément, Denis; Derchi, Lorenzo E; Eleftheroudi, Marianna; Levtchenko, Elena; Peters, Dorien; Van Poppel, Hendrik; Vanholder, Raymond (2018). European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrology, Dialysis, Transplantation, 33(4):563-573.

Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ronald D; Koch, Gary; Ouyang, John; McQuade, Robert D; Blais, Jaime D; Czerwiec, Frank S; Sergeyeva, Olga (2017). Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 377(20):1930-1942.

Grantham, Jared J; Chapman, Arlene B; Blais, Jaime; Czerwiec, Frank S; Devuyst, Olivier; Gansevoort, Ron T; Higashihara, Eiji; Krasa, Holly; Zhou, Wen; Ouyang, John; Perrone, Ronald D; Torres, Vicente E (2017). Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 32(6):969-975.

Devuyst, Olivier; Chapman, Arlene B; Gansevoort, Ron T; Higashihara, Eiji; Perrone, Ronald D; Torres, Vicente E; Blais, Jaime D; Zhou, Wen; Ouyang, John; Czerwiec, Frank S (2017). Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology (JASN), 28(5):1592-1602.

Levin, Adeera; Tonelli, Marcello; Bonventre, Joseph; Coresh, Josef; Donner, Jo-Ann; Fogo, Agnes B; Fox, Caroline S; Gansevoort, Ron T; Heerspink, Hiddo J L; Jardine, Meg; Kasiske, Bertram; Köttgen, Anna; Kretzler, Matthias; Levey, Andrew S; Luyckx, Valerie Ann; Mehta, Ravindra; Moe, Orson; Obrador, Gregorio; Pannu, Neesh; Parikh, Chirag R; Perkovic, Vlado; Pollock, Carol; Stenvinkel, Peter; Tuttle, Katherine R; Wheeler, David C; Eckardt, Kai-Uwe; Adu, Dwomoa; Agarwal, Sanjay Kumar; Alrukhaimi, Mona; Anders, Hans-Joachim; et al (2017). Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 390(10105):1888-1917.

Torres, Vicente E; Devuyst, Olivier; Chapman, Arlene B; Gansevoort, Ron T; Perrone, Ronald D; Ouyang, John; Blais, Jaime D; Czerwiec, Frank S; Sergeyeva, Olga (2017). Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 45(3):257-266.

Pena, Michelle J; Stenvinkel, Peter; Kretzler, Matthias; Adu, Dwomoa; Agarwal, Sanjay Kumar; Coresh, Josef; Feldman, Harold I; Fogo, Agnes B; Gansevoort, Ron T; Harris, David C; Jha, Vivekanand; Liu, Zhi-Hong; Luyckx, Valerie A; Massy, Ziad A; Mehta, Ravindra; Nelson, Robert G; O'Donoghue, Donal J; Obrador, Gregorio T; Roberts, Charlotte J; Sola, Laura; Sumaili, Ernest K; Tatiyanupanwong, Sajja; Thomas, Bernadette; Wiecek, Andrzej; Parikh, Chirag R; Heerspink, Hiddo J L (2017). Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. Kidney International Supplements, 7(2):107-113.

Casteleijn, Niek F; Blais, Jaime D; Chapman, Arlene B; Czerwiec, Frank S; Devuyst, Olivier; Higashihara, Eiji; Leliveld, Anna M; Ouyang, John; Perrone, Ronald D; Torres, Vicente E; Gansevoort, Ron T (2017). Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. American Journal of Kidney Diseases, 69(2):210-219.

Gansevoort, Ron T; Meijer, Esther; Chapman, Arlene B; Czerwiec, Frank S; Devuyst, Olivier; Grantham, Jared J; Higashihara, Eiji; Krasa, Holly B; Ouyang, John; Perrone, Ronald D; Torres, Vicente E (2016). Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrology, Dialysis, Transplantation, 31(11):1887-1894.

Gansevoort, Ron T; Arici, Mustafa; Benzing, Thomas; Birn, Henrik; Capasso, Giovambattista; Covic, Adrian; Devuyst, Olivier; Drechsler, Christiane; Eckardt, Kai-Uwe; Emma, Francesco; Knebelmann, Bertrand; Le Meur, Yannick; Massy, Ziad A; Ong, Albert C.M; Ortiz, Alberto; Schaefer, Franz; Torra, Roser; Vanholder, Raymond; Więcek, Andrzej; Zoccali, Carmine; Van Biesen, Wim (2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology, Dialysis, Transplantation, 31(3):337-348.

Chapman, Arlene B; Devuyst, Olivier; Eckardt, Kai-Uwe; Gansevoort, Ron T; Harris, Tess; Horie, Shigeo; Kasiske, Bertram L; Odland, Dwight; Pei, York; Perrone, Ronald D; Pirson, Yves; Schrier, Robert W; Torra, Roser; Torres, Vicente E; Watnick, Terry; Wheeler, David C (2015). Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney International, 88(1):17-27.

Petzold, Katja; Gansevoort, Ron T; Ong, Albert C M; Devuyst, Olivier; Rotar, Laura; Eckardt, Kai-Uwe; Köttgen, Anna; Pirson, Yves; Remuzzi, Giuseppe; Sandford, Richard; Tesar, Vladimir; Ecder, Tevfik; Chaveau, Dominique; Torra, Roser; Budde, Klemens; Le Meur, Yannick; Wüthrich, Rudolf P; Serra, Andreas L (2014). Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology, Dialysis, Transplantation, 29 Suppl:iv26-iv32.

Spithoven, Edwin M; Kramer, Anneke; Meijer, Esther; Orskov, Bjarne; Wanner, Christoph; Abad, Jose M; Aresté, Nuria; de la Torre, Ramón Alonso; Caskey, Fergus; Couchoud, Cécile; Finne, Patrik; Heaf, James; Hoitsma, Andries; de Meester, Johan; Pascual, Julio; Postorino, Maurizio; Ravani, Pietro; Zurriaga, Oscar; Jager, Kitty J; Gansevoort, Ron T (2014). Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of data from the ERA-EDTA Registry. Nephrology, Dialysis, Transplantation, 29 Suppl:iv15-iv25.

Spithoven, Edwin M; Kramer, Anneke; Meijer, Esther; Orskov, Bjarne; Wanner, Christoph; Caskey, Fergus; Collart, Frederic; Finne, Patrik; Fogarty, Damian G; Groothoff, Jaap W; Hoitsma, Andries; Nogier, Marie-Béatrice; Postorino, Maurizio; Ravani, Pietro; Zurriaga, Oscar; Jager, Kitty J; Gansevoort, Ron T (2014). Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 86(6):1244-1252.

Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Grantham, Jared J; Higashihara, Eiji; Perrone, Ronald D; Krasa, Holly B; Ouyang, John; Czerwiec, Frank S (2012). Tolvaptan in patients with autosomal dominant polycystic kidney disease. The New England Journal of Medicine, 367(25):2407-2418.

This list was generated on Thu Aug 16 12:36:25 2018 CEST.